The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer
Open accessAbstract
Abstract Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP inhibitor–induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC). We demonstrate that the PARP inhibitor olaparib induces CD8+ T-cell infiltration and activation in vivo, and that CD8+ T-cell depletion severely compromises antitumor efficacy. Olaparib-induced T-cell recruitment is mediated through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and is more pronounced in HR-deficient compared with HR-proficient TNBC cells and in vivo models. CRISPR-mediated knockout of STING in cancer cells prevents proinflammatory signaling and is sufficient to abolish olaparib-induced T-cell infiltration in vivo. These findings elucidate an additional mechanism of action of PARP inhibitors and provide a rationale for combining PARP inhibition with immunotherapies for the treatment of TNBC. Significance: This work demonstrates cross-talk between PARP inhibition and the tumor microenvironment related to STING/TBK1/IRF3 pathway activation in cancer cells that governs CD8+ T-cell recruitment and antitumor efficacy. The data provide insight into the mechanism of action of PARP inhibitors in BRCA-associated breast cancer. This article is highlighted in the In This Issue feature, p. 681
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various FDA-approved and experimental PARP inhibitors have been shown to drive robust type I IFN secretion downstream of increased cytosolic availability of ssDNA or micronuclei (DNAcontaining structures generally formed by faulty mitoses) in a variety of tumors, including (but not limited to) BRCA1- and BRCA2-deficient neoplasms (Chabanon et al., 2019; Ding et al., 2018; Pantelidou et al., 2019;”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Pantelidou et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it has been proposed that tumor cell-intrinsic STING enhances tumor immunogenicity by increasing immune cell activation and triggering tumor cell regression.47–49”
From Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation (2023) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous studies have suggested that the tumor cell-intrinsic STING pathway may be essential in triggering antitumor immunity in other contexts.47–49”
From Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation (2023) · cites this paper as [47]
In the citing paper
“In some settings, this was accompanied by the release of T-cell chemoattractants, including CXCL10, as well as by paracrine STING activation in DCs, ultimately leading to upregulation of MHC class II molecules and co-stimulatory ligands in support of T-cell priming (Ding et al., 2018; Pantelidou et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Pantelidou et al., 2019
In the citing paper
“Firstly, PARPi activates cGAS-STING pathway in cancer cells and increases T cell recruitment [224].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [224]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902 · cited 2×
“Similar findings were observed with the CHK1 inhibitor prexasertib in SCLC models (37), suggesting that STING pathway activation may be a common mechanism among DNA damage–repair inhibitors.”
BackgroundResultTriple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 783
Konno, H., Konno, K., & Barber, G. N. (2013) · Cell · doi:10.1016/j.cell.2013.09.049 · Cited by 687
Dobbs, N., Burnaevskiy, N., Chen, D., Gonugunta, V. K., Alto, N. M., & Yan, N. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.07.001 · Cited by 630
Shen, J., Zhao, W., Ju, Z., Wang, L., Peng, Y., Labrie, M., Yap, T. A., Mills, G. B., & Peng, G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1003 · Cited by 591
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · cited 3×
“In contrast, although potent STING pathway activation in response to olaparib was observed in DCs derived from ID8/BRCA1-null tumors and from a Trp53–/–, Brca1–/–, Mycoverexpressing ovarian GEMM, leading to T-cell recruitment, these events did not occur in BRCA-proficient models (31).”
BackgroundResultClass IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558 · cited 1×
“Compensation was performed manually on BD FACSDiva using single color and isotype controls, in line with our previous work (43).”
MethodLoss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
Direct Effects of Type I Interferons on Cells of the Immune System
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 503
Prabakaran, T., Bodda, C., Krapp, C., Zhang, B., Christensen, M. H., Sun, C., Reinert, L., Cai, Y., Jensen, S. B., Skouboe, M. K., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201797858 · Cited by 489
The host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487
Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F. A., Peterse, J. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702969104 · Cited by 474
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123319 · Cited by 332
Ono, M., Tsuda, H., Shimizu, C., Yamamoto, S., Shibata, T., Yamamoto, H., Hirata, T., Yonemori, K., Ando, M., Tamura, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1554-7 · Cited by 308
Johnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.077 · Cited by 291
Self-citationCTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 285
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305170110 · Cited by 265
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Wang, Z., Sun, K., Xiao, Y., Feng, B., Mikule, K., Ma, X., Feng, N., Vellano, C. P., Federico, L., Marszalek, J. R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38534-6 · Cited by 253 · cited 1×
“In contrast, in a BRCA1-deficient TNBC humanized mouse xenograft model PARP inhibition was associated with an increased T cell infiltrate and activated interferon signaling (8).”
BackgroundMolecular basis of Tank-binding kinase 1 activation by transautophosphorylation
Ma, X., Helgason, E., Phung, Q. T., Quan, C. L., Iyer, R. S., Lee, M. W., Bowman, K. K., Starovasnik, M. A., & Dueber, E. C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121552109 · Cited by 236
Servant, M. J., Grandvaux, N., tenOever, B. R., Duguay, D., Lin, R., & Hiscott, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209851200 · Cited by 216
Role of the cGAS–STING pathway in cancer development and oncotherapeutic approaches
Khoo, L. T., & Chen, L. (2018) · The EMBO Reports · doi:10.15252/embr.201846935 · Cited by 204
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Kotsopoulos, J., Huzarski, T., Gronwald, J., Singer, C. F., Moller, P., Lynch, H. T., Armel, S., Karlan, B., Foulkes, W. D., Neuhausen, S. L., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw177 · Cited by 197
Huang, J., Wang, L., Cong, Z., Amoozgar, Z., Kiner, E., Xing, D., Oršulić, S., Matulonis, U. A., & Goldberg, M. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.083 · Cited by 153
Mulligan, A. M., Raitman, I., Feeley, L., Pinnaduwage, D., Nguyen, L. T., O’Malley, F. P., Ohashi, P. S., & Andrulis, I. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3314 · Cited by 143
Konstantinopoulos, P. A., Waggoner, S. E., Vidal, G. A., Mita, M. M., Fleming, G. F., Holloway, R. W., Le, L. V., Sachdev, J. C., Chapman‐Davis, E., Colón‐Otero, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.106 · Cited by 143
Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies
Iurescia, S., Fioretti, D. P., & Rinaldi, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00711 · Cited by 126
RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
Wang, Y., Krais, J. J., Bernhardy, A. J., Nicolas, É., Cai, K. Q., Harrell, M. I., Kim, H. H., George, E. M., Swisher, E. M., Simpkins, F. A., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87033 · Cited by 114
Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer
Araujo, J. M., Gomez, A. C., Aguilar, A., Salgado, R., Balko, J. M., Bravo, L., Doimi, F., Bretel, D., Morante, Z., Flores, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23099-7 · Cited by 108
Self-citationPostel-Vinay, S. C., Bajrami, I., Friboulet, L., Elliott, R. J. R., Fontebasso, Y., Dorvault, N., Olaussen, K. A., André, F., Soria, J., Lord, C. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.311 · Cited by 105
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
Juvekar, A., Hu, H., Yadegarynia, S., Lyssiotis, C. A., Ullas, S., Lien, E. C., Bellinger, G., Son, J., Hok, R. C., Seth, P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522223113 · Cited by 93
Self-citationVinayak, S., Tolaney, S. M., Schwartzberg, L. S., Mita, M. M., McCann, G. A.-L., Tan, A. R., Wahner Hendrickson, A. E., Forero-Torres, A., Anders, C. K., Wulf, G. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1011 · Cited by 77 · cited 1×
“Notably, the majority of TNBC clinical responses to niraparib/pembrolizumab occurred among patients harboring BRCA mutations (6).”
BackgroundLee, H. J., Lee, J.-J., Song, I. H., Park, I. A., Kang, J. K., Yu, J. H., Ahn, J., & Gong, G. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3438-8 · Cited by 75
cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response
Bose, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112456 · Cited by 70
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors
Barazas, M., Gasparini, A., Huang, Y., Küçükosmanoğlu, A., Annunziato, S., Bouwman, P., Sol, W., Kersbergen, A. J., Proost, N., de Korte‐Grimmerink, R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2077 · Cited by 58
Póti, Á., Berta, K., Xiao, Y., Pipek, O., Klus, G. T., Ried, T., Csabai, I., Wilcoxen, K., Mikule, K. W., Szállási, Z., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0312-6 · Cited by 27
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Breast Cancer
Kwa, M. J., & Adams, S. (2016) · Current Breast Cancer Reports · doi:10.1007/s12609-016-0198-3 · Cited by 11
Research works printed but not linked: 1
- Ferreira, 2010., ImageJ user guide-IJ 1.46
Cited by
Molecular mechanisms and cellular functions of cGAS–STING signalling
Hopfner, K.-P., & Hornung, V. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0244-x · Cited by 2,052
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
Kwon, J., & Bakhoum, S. F. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0761 · Cited by 1,293
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Gay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lu, W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.014 · Cited by 962
Metadata
- Authors
- Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., Cheney, E. M., Bouwman, P., Jonkers, J., Rottenberg, S., Guerriero, J. L., Wulf, G. M., & Shapiro, G. I.
- Affiliations
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- 2Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
- Dana-Farber Cancer Institute (US)
- 4Breast Tumor Immunology Laboratory, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.
- The Netherlands Cancer Institute (NL)
- University of Bern (CH)
- Brigham and Women's Hospital (US)
- Corresponding author
- Shapiro, Geoffrey I.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2019-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 722-737
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6548644
- OpenAlex
- W2942052760
- Cited by
- 743
- References
- 44
- Citations by year
- 2026: 106 · 2025: 83 · 2024: 110 · 2023: 112 · 2022: 119 · 2021: 120 · 2020: 73 · 2019: 20
- FWCI
- 34.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (P50 CA168504, R01 CA090687, R01 CA226776)
- Susan G. Komen for the CureSusan G. Komen for the Cure (Susan G. Komen) (CCR18547597)
- EC | European Research CouncilEC | European Research Council (ERC) (CoG-681572)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- PARP inhibitors, olaparib, triple-negative breast cancer, BRCA1 deficiency, CD8+ T cell recruitment, cGAS-STING pathway, tumor microenvironment, dendritic cells, combination immunotherapy, antitumor immunity
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, STING Protein, Female, Humans, Immunohistochemistry, Membrane Proteins, Signal Transduction, Biomarkers, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, BRCA1 Protein, BRCA2 Protein, Tumor Microenvironment, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.